Vera Therapeutics (VERA) Profit After Tax (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Profit After Tax data on file, last reported at -$121.0 million in Q1 2026.

• Quarterly Profit After Tax fell 134.13% year-over-year to -$121.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$368.6 million (down 111.88% YoY) and the FY2025 annual result came in at -$299.6 million, down 96.92% from the prior year.
• Profit After Tax retreated to -$121.0 million in Q1 2026, from -$91.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$14.9 million in Q2 2022 to a low of -$121.0 million in Q1 2026.
• A 5-year average of -$44.5 million and a median of -$32.4 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax sank 332.15% — and 2023, when it increased 21.55%.
• Tracing VERA's Profit After Tax over 5 years: stood at -$32.4 million in 2022, then advanced by 21.55% to -$25.4 million in 2023, then tumbled by 70.94% to -$43.4 million in 2024, then slumped by 109.78% to -$91.1 million in 2025, then slumped by 32.86% to -$121.0 million in 2026.
• The last three Profit After Tax figures came in at -$121.0 million (Q1 2026), -$91.1 million (Q4 2025), and -$79.9 million (Q3 2025), per Business Quant data.